Labcorp Holdings Inc. (LH) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offer...
Labcorp Holdings Inc. (LH) currently trades at a P/E ratio of 25.73 (historical range: 7.94–56.95, median: 25.26), placing it at the 52th percentile — near its historical average, P/S ratio of 1.80 (range: 1.17–2.13, 87th percentile — expensive relative to its history), EV/EBITDA of 21.69 (range: 7.05–39.12, 61th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Labcorp Holdings Inc.'s P/E ratio has expanded by 142% over the observed period (from an average of 14.6 to 35.5).
Labcorp Holdings Inc. trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 25.73 | 25.26 | 52th | near its historical average |
| P/S Ratio | 1.80 | 1.55 | 87th | expensive relative to its history |
| EV/EBITDA | 21.69 | 20.01 | 61th | above its historical average |
| FCF Yield | 4.48% | 6.07% | 25th | above its historical average |
Labcorp Holdings Inc. (LH) Valuation & P/E History
Labcorp Holdings Inc. (LH) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry currently trading at $317.95 with a market capitalization of $25.8 billion. This page provides historical valuation analysis for LH based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 25.73 is above the historical median of 25.26, placing LH at the 52th percentile of its valuation range. The P/S ratio of 1.80 compares to a median of 1.55.
LH Valuation Metrics & Historical Range
The valuation table above shows Labcorp Holdings Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether LH is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests LH is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Labcorp Holdings Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is LH Overvalued or Undervalued?
Labcorp Holdings Inc. trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 67 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive LH is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full LH analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.LH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.